Droxidopa Mechanism of Action
Droxidopa is a synthetic amino acid prodrug that is directly metabolized to norepinephrine by dopa-decarboxylase (DDC), which then increases blood pressure by inducing peripheral arterial and venous vasoconstriction. 1
How Droxidopa Works
Droxidopa (L-threo-3,4-dihydroxyphenylserine) functions as a norepinephrine precursor that bypasses the rate-limiting steps in catecholamine synthesis. The drug is converted to norepinephrine through a single enzymatic step by dopa-decarboxylase, an enzyme extensively distributed throughout the body 1.
Key Mechanistic Points:
- Direct conversion pathway: Unlike other sympathomimetics, droxidopa is directly metabolized to norepinephrine without requiring multiple enzymatic steps
- Site of action: The conversion occurs in nerve endings and other tissues where dopa-decarboxylase is present 2
- Pharmacological effect: Droxidopa exerts its therapeutic effects through norepinephrine, not through the parent molecule or other metabolites 1
- Pressor mechanism: The resulting norepinephrine increases blood pressure by inducing peripheral arterial and venous vasoconstriction 1
Metabolic Pathways
The metabolism of droxidopa follows the catecholamine pathway and does not involve the cytochrome P450 system 1. Three primary metabolic routes exist:
- Conversion to norepinephrine by DOPA decarboxylase (DDC) - the therapeutically relevant pathway
- Methylation to 3-OM-DOPS by catechol-O-methyltransferase (COMT) - producing the major metabolite
- Conversion to protocatechualdehyde by DOPS aldolase
Clinical Pharmacodynamics
After oral administration, droxidopa produces small and transient rises in plasma norepinephrine levels, typically peaking 3-4 hours post-dose but remaining generally very low (<1 ng/mL) and variable 1. Despite these modest systemic norepinephrine increases, peak droxidopa plasma concentrations correlate with increases in both systolic and diastolic blood pressures 1.
Important Clinical Caveat:
The exact mechanism by which droxidopa treats neurogenic orthostatic hypotension remains unknown 1. While the drug is believed to work through norepinephrine-mediated vasoconstriction, the contribution of other metabolites to its pharmacological effects is not well understood 1.
Therapeutic Application
Droxidopa is indicated for neurogenic orthostatic hypotension, where it improves symptoms in conditions including Parkinson disease, pure autonomic failure, and multiple system atrophy 3. The drug can cross the blood-brain barrier according to preclinical studies 1, though its primary therapeutic effect appears to be peripheral vasoconstriction.
Drug Interaction Note:
Carbidopa, a peripheral dopa-decarboxylase inhibitor used in Parkinson disease, may decrease droxidopa's effectiveness by blocking its conversion to norepinephrine 3. This represents a critical consideration when prescribing droxidopa to patients already on carbidopa-containing medications.